KRAS and pancreatic neoplasm: To investigate the contribution of HIPK2 to oncogenic KRAS-driven tumorigenesis in the onset of pancreatic cancer, we first assessed the expression of HIPK2 in human PDACs by WB, employing highly specific anti-HIPK2 Ab previously validated on human HIPK2-null cells [27] and tissue microarrays [19].